Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Khanh Tu Do"'
Autor:
Jing Y. Wang, Leena Gandhi, Rentian Wu, Martin Gutierrez, Ji Hyun Lee, Kaiming Sun, Jike Cui, Khanh Tu Do, Jennifer Truong, Xiaolin Fan, Nehal Lakhani, Ronda Rippley, Patrick Trojer, Suresh Bobba, Drew W. Rasco, Linda R. Duska, Manish R. Sharma, Kyriakos P. Papadopoulos
Publikováno v:
Journal of Clinical Oncology. 39:3104-3104
3104 Background: Enhancer of Zeste homolog 2 (EZH2) is a histone methyltransferase and the catalytic subunit of Polycomb Repressive Complex 2 (PRC2). EZH2 is frequently overexpressed in cancers and correlates with poor prognosis. CPI-0209 is an oral,
Autor:
Antonio Jimeno, Robert S. Meehan, Sima Zacharek, Todd M. Bauer, Khanh Tu Do, Salomon M. Stemmer, Patricia LoRusso, Ravit Geva, Honghong Zhou, Ryan J. Sullivan, Pamela Cohen, Joshua Frederick, Manish R. Patel, Andressa S. Laino, Ding Wang, William Randolph, Corinne Maurice-Dror, Jing Sun
Publikováno v:
Journal of Clinical Oncology. 38:3092-3092
3092 Background: mRNA-2752 is a novel mRNA-based therapeutic agent encoding OX40L T cell co-stimulator, IL-23 and IL-36γ pro-inflammatory cytokines. Here we present findings from a first-in-human study of iTu mRNA-2752 in solid tumor patients as mon
Autor:
Geoffrey I. Shapiro, Jacob M. Estes, Frank Tsai, Erkut Borazanci, James M. Cleary, Suma Satti, Sunil Sharma, Takumi Kawabe, Justin C. Moser, Lingling Du, Vivek Khemka, Khanh Tu Do, Marc R. Matrana, Valentin Kolmakov
Publikováno v:
Journal of Clinical Oncology. 38:3059-3059
3059 Background: CBP501 is a 12-amino acid G2 checkpoint abrogator and calmodulin-modulating peptide that increases platinum influx into tumor cells and induces tumor immunogenic cell death. CBP501 also suppresses platinum-induced release of cytokine
Autor:
Ryan J. Sullivan, Keith T. Flaherty, Khanh Tu Do, Leanne G. Ahronian, J.M. Cleary, Joseph M. Gurski, E. Van Seventer, Jeffrey W. Clark, Ursula A. Matulonis, Gianluca Mauri, Aparna Raj Parikh, Ryan B. Corcoran, J. Veneris, Colin D. Weekes, Oladapo Yeku, Geoffrey I. Shapiro, Rebecca S. Heist, Dejan Juric, Isobel J Fetter
Publikováno v:
Annals of Oncology. 30:v164
Background MEK inhibitors (MEKi) lack single agent clinical efficacy in RAS mutant cancers, likely because MEKi produce only a cytostatic response in preclinical RAS mutant cancer models. BCL-XL is an anti-apoptotic BCL2 family protein identified by
Autor:
Amy Gallant, Teresa J. Mazeika, Audrea Szabatura, Alan H. Breaud, Hakim Lakhani, Garrett Rompelman, Khanh Tu Do, Anna Shanedling, Laura Cedro, Caryn M Caparrotta, Sylvia Bartel
Publikováno v:
Journal of Clinical Oncology. 37:257-257
257 Background: At Dana-Farber Cancer Institute (DFCI), timing of order release to the pharmacy is a contributing factor to safety and processing concerns for oral investigational medications. Day-of release can lead to delayed delivery to the patien
Autor:
Len Neckers, John L. Hays, Jennifer Hedglin, Khanh Tu Do, Geraldine O'Sullivan, Jane B. Trepel, Alice P. Chen, Andrew Wolanski, Stephen V. Liu, Min-Jung Lee, Kristin Beebe, Jeffrey G. Supko, Elizabeth Downey, Geoffrey I. Shapiro, Alona Muzikansky, James H. Doroshow, Fernanda I. Arnaldez, Courtney Gannon, Susana M. Campos
Publikováno v:
Journal of Clinical Oncology. 37:2619-2619
2619 Background: The 90kDa heat shock protein (HSP90) participates in the folding, stabilization, activation, and proteolytic turnover of aberrant proteins that contribute to the growth and survival of cancer cells. HSP90 inhibition leads to degradat
Autor:
Gary K. Schwartz, Gideon Bollag, Brian A. Van Tine, Gulam Abbas Manji, Lauren Esther Blumberg, Alexander G. Raufi, Parag Patwardhan, Daniel Otap, Jennifer Wang, Shahnaz V. Singh-Kandah, Angela C. Hirbe, Naomi Sender, Khanh Tu Do, Shing Mirn Lee
Publikováno v:
Journal of Clinical Oncology. 37:11055-11055
11055 Background: No effective therapy exists for unresectable malignant peripheral nerve sheath tumors (MPNSTs). We previously reported that the combination of PEX and the mTOR inhibitor S synergistically inhibited MPNST growth (CCR 20: 3146, 2014)
Autor:
Arjun Mittra, Geraldine Helen O'Sullivan Coyne, Khanh Tu Do, Sarina Anne Piha-Paul, Shivaani Kummar, Naoko Takebe, Ashley Bruns, Lamin Juwara, Lawrence Rubinstein, Murielle Hogu, Robert J. Kinders, Ralph E. Parchment, Brandon Miller, Deborah Wilsker, M. Cecilia Monge B., Sabrina Sharmin Khan, L. Austin Doyle, James H. Doroshow, Alice P. Chen
Publikováno v:
Journal of Clinical Oncology. 37:3067-3067
3067 Background: M6620 (M), a potent ATR inhibitor, has synergistic activity with cisplatin (C) in multiple preclinical models, resulting in DNA damage and antitumor activity. We hypothesize that inhibition of both homologous recombination and base e
Autor:
John C. Morris, Patrick Hwu, Matthew S. Block, Sacha Gnjatic, H. Lu, Chet Bohac, Khanh Tu Do, Robin L. Jones, Seth M. Pollack, Shanta Chawla, Neeta Somaiah, Mihaela Druta, Joseph Kim
Publikováno v:
Annals of Oncology. 29:viii578
Autor:
Tamba Monrose, Suzanne Hector-Barry, Zachary Zwiesler, Priti Kumari, Tali Mazor, Geoffrey I. Shapiro, Khanh Tu Do, Catherine Del Vecchio Fitz, John Methot, James Lindsay, Michael J. Hassett, Adem Albayrak, Ethan Cerami
Publikováno v:
Cancer Research. 78:2288-2288
More than 1,100 phase I treatment trials are registered with clinicaltrials.cancer.gov. Patient identification and recruitment to these trials is particularly challenging due to the vast molecular data now available for patients and the increasingly